Xtant Medical Holdings, Inc. (XTNT)
Pre-Market:
- ACCESSWIRE
Xtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024
BELGRADE, MO / ACCESSWIRE / May 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial ...
- GlobeNewswire
Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™. “The launches of SimpliGraft and SimpliMax highlights the strength of our newly revitalized Research and Development team,” said Sean Browne, President and CEO of Xtant Medical. “We
- Insider Monkey
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2023 Earnings Call Transcript
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2023 Earnings Call Transcript April 1, 2024 Xtant Medical Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.03 EPS, expectations were $-0.025. Xtant Medical Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). […]
